10-K: Tyra Biosciences Reports 2024 Financial Results and Provides Business Update

Tyra Biosciences details its financial performance for 2024 and highlights key advancements in its clinical-stage precision medicine programs.

Summary

• Tyra Biosciences, a clinical-stage biotechnology company, reported a net loss of $86.5 million for the year ended December 31, 2024, compared to a net loss of $69.1 million for the previous year.
• The company's research and development expenses increased to $80.1 million in 2024 from $62.5 million in 2023, driven by the advancement of its clinical programs.
• General and administrative expenses also rose to $24.1 million in 2024 from $17.4 million in 2023, reflecting increased personnel and public company costs.
• As of December 31, 2024, Tyra Biosciences had cash, cash equivalents, and marketable securities totaling $341.4 million, which is expected to fund operations through at least 2027.
• The company is advancing three clinical-stage programs: TYRA-300 for bladder cancer and skeletal conditions, TYRA-200 for intrahepatic cholangiocarcinoma (ICC), and TYRA-430 for hepatocellular carcinoma (HCC).
• Tyra expects to dose the first patient in the SURF302 (NMIBC) and BEACH301 (ACH) studies in the second quarter of 2025.
• Tyra expects to dose the first patient in the SURF431 (HCC) study in the second quarter of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is making progress in its clinical programs, it is also experiencing significant net losses and faces numerous risks and uncertainties.

Positives

• The company has a strong cash position of $341.4 million, providing a runway through at least 2027.
• TYRA-300 demonstrated a 54.5% confirmed partial response rate in FGFR3+ mUC patients in the SURF301 trial.
• The FDA cleared INDs for TYRA-300 in NMIBC and ACH, and for TYRA-430 in HCC, allowing for Phase 2 and Phase 1 trials, respectively.
• The company's SNP platform enables rapid and precise drug design, potentially leading to more effective and tolerable therapies.

Negatives

• The company experienced a significant net loss of $86.5 million in 2024.
• The company has not generated any revenue to date and does not expect to generate any revenue from product sales unless and until it successfully completes the development of and obtains regulatory approval for its product candidates, which will not be for several years, if ever.
• The company's accumulated deficit is $251.3 million as of December 31, 2024.

Risks

• The company is early in its development efforts and has not completed any clinical trials.
• The company will require substantial additional capital to achieve its goals.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The trading price of the shares of the company's common stock could be highly volatile.

Future Outlook

The company expects its cash, cash equivalents, and marketable securities to fund operations through at least 2027 and plans to continue advancing its clinical programs and expanding its pipeline.

Industry Context

Tyra Biosciences is operating in the competitive fields of precision oncology and genetically defined conditions, where numerous companies are developing treatments, including small molecule drugs, biologics, and cellular therapies. The company is focused on developing next-generation precision medicines to overcome the limitations of existing therapies.

Comparison to Industry Standards

• The company's approach to drug discovery using its SNP platform is novel and unproven, making it difficult to compare directly to industry standards.
• The company faces competition from approved therapies such as Janssen Pharmaceuticals' Balversa (erdafitinib) for mUC and BioMarin's Voxzogo for ACH.
• The company's FGFR inhibitor programs compete with other isoform-specific FGFR inhibitors in development, such as Eli Lilly's LOXO-435 and Elevars Therapeutics' lirafugratinib.
• The company's FGFR4 inhibitor program competes with other FGFR4 programs in clinical development, primarily in China, including CStone Pharmaceuticals and Blueprint Medicines' BLU-554 (fisogatinib).

Related Party Transactions

• RA Capital Healthcare Fund, L.P. (RA Capital) is considered a related party to the Company because Jake Simson, Ph.D. is a member of the Company's board of directors and a partner at RA Capital.
• In connection with the 2024 Private Placement, the Company issued 3,180,155 shares of common stock and pre-funded warrants to purchase 1,538,457 shares of the Company's common stock to RA Capital, resulting in aggregate gross proceeds of approximately $ 61.4 million.
• Boxer Capital, LLC (Boxer Capital) was considered a related party to the Company because, at the time of the 2024 Private Placement closing, Siddarth Subramony, Ph.D., was a member of the Company's board of directors and a managing director of Boxer Capital.
• In connection with the 2024 Private Placement, the Company issued 63,412 shares of common stock and pre-funded warrants to purchase 705,280 shares of the Company's common stock to Boxer Capital, resulting in aggregate gross proceeds of approximately $ 10.0 million.
• During the year ended December 31, 2024, Boxer Capital exercised 705,043 of 2024 Pre-Funded Warrants in cashless transactions, which resulted in 705,000 shares of common stock being issued to Boxer Capital.
• Nextech VI Oncology SCSP is considered a related party to the Company because Melissa McCracken, Ph.D., is a member of the Company's board of directors and a principal at Nextech Invest Ltd. (an affiliate of Nextech VI Oncology SCSP).
• In connection with the 2024 Private Placement, the Company issued 1,537,279 shares of common stock to Nextech VI Oncology SCSP, resulting in aggregate gross proceeds of approximately $ 20.0 million.
• On October 18, 2024, the Company entered into an exchange agreement with Boxer Capital and RA Capital, the Company's stockholders and related parties to the Company at the time of the exchange.
• Pursuant to the exchange agreement (i) Boxer Capital agreed to exchange 2,000,000 shares of the Companys common stock for one or more pre-funded warrants to acquire an aggregate of 2,000,000 shares of common stock and (ii) RA Capital agreed to exchange 1,000,000 shares of common stock for one or more pre-funded warrants to acquire an aggregate of 1,000,000 shares of common stock (each of such pre-funded warrants an Exchange Warrant and collectively the Exchange Warrants, and such exchanges of common stock for Exchange Warrants collectively the Exchange).

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's growth and development activities will create opportunities for employees.
• Patients: The company's development of new therapies has the potential to improve outcomes for patients with cancer and genetically defined conditions.
• Suppliers: The company's research and development activities will generate demand for suppliers of laboratory equipment, materials, and services.
• Creditors: The company's financial stability and ability to raise capital will impact its ability to meet its obligations to creditors.

Next Steps

• Continue dose optimization in the SURF301 trial for mUC.
• Dose the first patient in the SURF302 trial for NMIBC in the second quarter of 2025.
• Dose the first child in the BEACH301 trial for ACH in the second quarter of 2025.
• Dose the first patient in the SURF431 trial for HCC in the second quarter of 2025.
• Continue leveraging the SNP platform for discovery and development of additional preclinical programs.

Key Dates

Keywords

TYRA-300, TYRA-200, TYRA-430, FGFR, bladder cancer, achondroplasia, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, clinical trials, precision medicine, biotechnology, oncology, SNP platform, financial results